• Title/Summary/Keyword: Department of Radiology

Search Result 9,188, Processing Time 0.032 seconds

Giant Serpentine Intracranial Aneurysm: A Case Report

  • Jae Seong Park;Myeong Sub Lee;Myung Soon Kim;Dong Jin Kim;Joong Wha Park;Kum Whang
    • Korean Journal of Radiology
    • /
    • v.2 no.3
    • /
    • pp.179-182
    • /
    • 2001
  • The authors present a case of giant serpentine aneurysm (a partially thrombosed aneurysm containing tortuous vascular channels with a separate entrance and outflow pathway). Giant serpentine aneurysms form a subgroup of giant intracranial aneurysms, distinct from saccular and fusiform varieties, and in this case, too, the clinical presentation and radiographic features of CT, MR imaging and angiography were distinct.

  • PDF

Guidelines for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging (KOSCI) - Part 2: Interpretation of Cine, Flow, and Angiography Data

  • Lee, Jae Wook;Hur, Jee Hye;Yang, Dong Hyun;Lee, Bae Young;Im, Dong Jin;Hong, Su Jin;Kim, Eun Young;Park, Eun-Ah;Jo, Yeseul;Kim, Jeong Jae;Park, Chul Hwan;Yong, Hwan Seok
    • Investigative Magnetic Resonance Imaging
    • /
    • v.23 no.4
    • /
    • pp.316-327
    • /
    • 2019
  • Cardiovascular magnetic resonance imaging (CMR) is expected to be increasingly used in Korea due to technology advances and the expanded national insurance coverage of these tests. For improved patient care, it is crucial not only that CMR images are properly acquired but that they are accurately interpreted by well-trained personnel. In response to the increased demand for CMR, the Korean Society of Cardiovascular Imaging (KOSCI) has issued interpretation guidelines in conjunction with the Korean Society of Radiology (KSR). KOSCI has also created a formal Committee on CMR Guidelines to write updated practices. The members of this Committee review previously published interpretation guidelines and discuss the patterns of CMR use in Korea.

Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective

  • Gun Ha Kim;Jin Hyoung Kim;Pyeong Hwa Kim;Hee Ho Chu;Dong Il Gwon;Heung-Kyu Ko
    • Korean Journal of Radiology
    • /
    • v.22 no.11
    • /
    • pp.1822-1833
    • /
    • 2021
  • This is a narrative review of various treatment modalities for advanced hepatocellular carcinoma (HCC), with a focus on recent updates in radiological treatments, as well as novel treatment concepts related to immune checkpoint inhibitors and combination therapies with locoregional treatments. Interventional radiologists have made efforts toward developing alternative and/or combination treatments for first-line systemic treatment of patients with advanced HCC. Locoregional treatments with or without systemic therapy may be considered in the selected patients. Various treatment modalities for advanced HCC are emerging, and several randomized controlled trials, including those of combination treatments with immunotherapy, are ongoing.

Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma

  • Yasir M. Nouri;Jin Hyoung Kim;Hyun-Ki Yoon;Heung-Kyu Ko;Ji Hoon Shin;Dong Il Gwon
    • Korean Journal of Radiology
    • /
    • v.20 no.1
    • /
    • pp.34-49
    • /
    • 2019
  • Conventional transcatheter arterial chemoembolization (c-TACE) is a widely used first-line palliative treatment for patients with unresectable hepatocellular carcinoma (HCC). Despite the effectiveness of c-TACE, to date, technique and procedure scheduling has not yet been standardized. Drug-eluting microspheres (DEMs) were therefore introduced to ensure more sustained and tumor-selective drug delivery for permanent embolization. These DEMs can load various drugs and release them in a sustained manner over a prolonged period. This approach ensures the delivery of high concentrations of chemotherapeutic agents to tumors, without increasing systemic concentrations, and promote tumor ischemia and necrosis. This review summarizes the recent advances in the use of DEM-TACE to treat HCC.